| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CLEC9A; DNGR1; DNGR-1; UNQ9341 |
| Entrez GeneID | 283420 |
| clone | 2H6H10 |
| WB Predicted band size | 27.3kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD370 (AA: extra 57-241) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与CD370(CLEC9A)抗体相关的文献示例：
1. **标题**：*Targeting CLEC9A with antibody-drug conjugates in hematologic malignancies*
**作者**：Smith A, et al.
**摘要**：研究开发了一种靶向CLEC9A(CD370)的单克隆抗体-药物偶联物(ADC)，证明其在血液肿瘤模型中可特异性杀伤恶性细胞，并增强化疗敏感性。
2. **标题**：*CLEC9A-directed antibodies enhance cross-presentation in dendritic cells for antitumor immunity*
**作者**：Tanaka K, et al.
**摘要**：通过抗CLEC9A抗体将肿瘤抗原靶向递送至树突状细胞，显著激活CD8+ T细胞免疫应答，为癌症疫苗开发提供新策略。
3. **标题**：*Structural basis of CLEC9A recognition by a humanized monoclonal antibody for immune modulation*
**作者**：Chen L, et al.
**摘要**：解析了人源化抗CLEC9A抗体与CD370的结合表位及结构特征，揭示了其在自身免疫疾病中调节炎症反应的分子机制。
注：以上为模拟文献，实际研究需通过PubMed或Google Scholar检索关键词(如"CLEC9A antibody"或"anti-CD370")获取具体文献。
CD370. also known as CLEC9A (C-type lectin domain family 9 member A), is a transmembrane protein belonging to the C-type lectin receptor family. It is primarily expressed on dendritic cells (DCs), particularly the cDC1 subset, and functions as a pattern recognition receptor involved in immune surveillance. CD370 recognizes cytoskeletal components exposed on necrotic or damaged cells, such as filamentous actin (F-actin), enabling the immune system to detect cell death and initiate adaptive immune responses. This interaction facilitates antigen cross-presentation, a critical mechanism for activating CD8+ T cells against intracellular pathogens and tumors.
CD370 antibodies are tools developed to target this receptor for research and therapeutic applications. In research, they help elucidate CLEC9A's role in immune activation, tolerance, and its potential as a biomarker for specific DC subsets. Therapeutically, anti-CD370 antibodies are explored for cancer immunotherapy due to their ability to enhance antigen presentation or deliver tumor antigens directly to DCs. Some studies investigate antibody-drug conjugates (ADCs) or bispecific antibodies engaging CLEC9A to improve tumor targeting. Challenges include balancing immune activation with tolerance and optimizing specificity. Current research focuses on understanding CD370's signaling pathways and its potential in vaccines or combination therapies against malignancies and infectious diseases.
×
